Universe Pharmaceuticals (UPC) Competitors $3.84 -0.16 (-4.00%) Closing price 03:57 PM EasternExtended Trading$3.91 +0.07 (+1.82%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock UPC vs. ALBT, BMRA, MYNZ, SNOA, ELAB, NLSP, PRTG, INDP, ACXP, and ALZNShould you be buying Universe Pharmaceuticals stock or one of its competitors? The main competitors of Universe Pharmaceuticals include Avalon GloboCare (ALBT), Biomerica (BMRA), Mainz Biomed (MYNZ), Sonoma Pharmaceuticals (SNOA), PMGC (ELAB), NLS Pharmaceutics (NLSP), Portage Biotech (PRTG), Indaptus Therapeutics (INDP), Acurx Pharmaceuticals (ACXP), and Alzamend Neuro (ALZN). These companies are all part of the "pharmaceutical products" industry. Universe Pharmaceuticals vs. Its Competitors Avalon GloboCare Biomerica Mainz Biomed Sonoma Pharmaceuticals PMGC NLS Pharmaceutics Portage Biotech Indaptus Therapeutics Acurx Pharmaceuticals Alzamend Neuro Universe Pharmaceuticals (NYSE:UPC) and Avalon GloboCare (NASDAQ:ALBT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations. Is UPC or ALBT more profitable? Universe Pharmaceuticals has a net margin of 0.00% compared to Avalon GloboCare's net margin of -1,451.94%. Company Net Margins Return on Equity Return on Assets Universe PharmaceuticalsN/A N/A N/A Avalon GloboCare -1,451.94%N/A -75.12% Does the media refer more to UPC or ALBT? In the previous week, Avalon GloboCare had 2 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 2 mentions for Avalon GloboCare and 0 mentions for Universe Pharmaceuticals. Avalon GloboCare's average media sentiment score of 0.49 beat Universe Pharmaceuticals' score of 0.00 indicating that Avalon GloboCare is being referred to more favorably in the news media. Company Overall Sentiment Universe Pharmaceuticals Neutral Avalon GloboCare Neutral Do institutionals & insiders believe in UPC or ALBT? 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are owned by institutional investors. 57.4% of Universe Pharmaceuticals shares are owned by insiders. Comparatively, 37.3% of Avalon GloboCare shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, UPC or ALBT? Universe Pharmaceuticals has higher revenue and earnings than Avalon GloboCare. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUniverse Pharmaceuticals$19.29M0.11-$6.16MN/AN/AAvalon GloboCare$1.33M7.22-$7.90M-$19.96-0.13 Which has more risk and volatility, UPC or ALBT? Universe Pharmaceuticals has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500. SummaryUniverse Pharmaceuticals beats Avalon GloboCare on 6 of the 10 factors compared between the two stocks. Get Universe Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPC vs. The Competition Export to ExcelMetricUniverse PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.16M$876.45M$5.83B$21.34BDividend YieldN/A4.84%5.25%3.51%P/E RatioN/A1.1175.5729.41Price / Sales0.1126.51536.7749.78Price / CashN/A19.5637.4224.46Price / Book0.026.7711.534.54Net Income-$6.16M-$4.20M$3.29B$999.91M7 Day Performance2.40%1.29%0.44%0.86%1 Month Performance6.96%9.43%10.84%5.13%1 Year Performance-99.79%27.95%61.62%16.56% Universe Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPCUniverse PharmaceuticalsN/A$3.84-4.0%N/A-99.8%$2.16M$19.29M0.00220Gap UpALBTAvalon GloboCare1.5842 of 5 stars$2.03+0.5%N/A-54.5%$7.80M$1.33M-0.105Positive NewsGap DownBMRABiomerica0.3788 of 5 stars$3.02-3.7%N/A+2.5%$7.69M$5.31M-1.3060News CoverageGap DownMYNZMainz Biomed1.9165 of 5 stars$1.68-0.3%$14.00+735.8%-88.8%$7.67M$890K-0.0330SNOASonoma PharmaceuticalsN/A$4.59+3.0%N/A+38.4%$7.52M$14.29M-1.86180ELABPMGC0.6927 of 5 stars$4.91-13.4%N/A-99.7%$7.40M$1.71M-0.0118Gap DownNLSPNLS PharmaceuticsN/A$2.05-3.5%N/A+1,443.4%$7.36MN/A0.006News CoveragePRTGPortage Biotech0.6741 of 5 stars$7.00-2.8%N/A+168.7%$7.30MN/A-0.176Positive NewsINDPIndaptus Therapeutics2.7795 of 5 stars$6.44-0.9%$238.00+3,595.7%-93.4%$7.13MN/A-0.176ACXPAcurx Pharmaceuticals2.0405 of 5 stars$4.50-2.7%$31.00+589.5%-89.7%$7.13MN/A-0.423Short Interest ↑ALZNAlzamend Neuro2.411 of 5 stars$2.41-1.4%$45.00+1,771.1%-87.4%$6.97MN/A0.004Positive News Related Companies and Tools Related Companies ALBT Alternatives BMRA Alternatives MYNZ Alternatives SNOA Alternatives ELAB Alternatives NLSP Alternatives PRTG Alternatives INDP Alternatives ACXP Alternatives ALZN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:UPC) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Universe Pharmaceuticals INC Please log in to your account or sign up in order to add this asset to your watchlist. Share Universe Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
